Novo Nordisk Stock is a Big Money Favorite

Novo Nordisk Stock Reveals Strong Demand

Institutional volumes reveal plenty. For 1-year, NVO has enjoyed heavy institutional support.
Each green bar signals unusually large volumes in NVO shares, pushing the stock higher:

Plenty of health care names are under accumulation right now. You can see that with the strong YTD +3.75% performance in the Health Care Select SPDR Fund (XLV). But there’s a powerful fundamental backdrop going on with NVO.

Novo Nordisk Fundamental Analysis

Institutional support coupled with a healthy fundamental backdrop makes this company worth investigating. As you can see, NVO has had positive sales & EPS growth in recent years:

• 3-year sales growth rate (+20.6%)
• 3-year EPS growth rate (+27%)

Source: FactSet

EPS is estimated to ramp higher this year by +20.3%.

Now it makes sense why the stock has been powering to new heights. Novo is an earnings powerhouse.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long-term.

Novo Nordisk has been a top-rated stock at MAPsignals. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Top 20 report multiple times over the years. The blue bars below shows when NVO was a top pick…cutting through the noise:

Tracking unusual volumes reveals the power of money flows.

Follow the Big Money.

This is a trait that most outlier stocks exhibit…the superstars.

Novo Nordisk Price Prediction

The NVO rally began many months ago. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in NVO at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MAPsignals process here.